Table 2.
Tumor response post-TARE.
| Radiologic Tumor Response | RECIST | mRECIST | p-Value (χ2) |
|---|---|---|---|
| 3 months post-TARE | |||
| DC (CR + PR + SD) | 73.3% (22/30) | 80.0% (24/30) | 0.54 |
| ORR (CR + PR) | 13.3% (4/30) | 56.7% (17/30) | 0.0004 |
| PD | 26.7% (8/30) | 20.0% (6/30) | |
| 6 months post-TARE | |||
| DC (CR + PR + SD) | 64.0% (16/25) | 68.0% (17/25) | 0.76 |
| ORR (CR + PR) | 20.0% (5/25) | 52.0% (13/25) | 0.02 |
| PD | 36.0% (9/25) | 32.0% (8/25) | |
| 9 months post-TARE | |||
| DC (CR + PR + SD) | 40.0% (6/15) | 46.7% (7/15) | 0.46 |
| ORR (CR + PR) | 13.3% (2/15) | 40.0% (6/15) | 0.09 |
| PD | 60.0% (9/15) | 53.3% (8/15) |
TARE, trans-arterial radioembolization; RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, Modified Response Evaluation Criteria in Solid Tumors; DC, disease control; CR, complete response; PR, partial response; SD, stable disease; PD, disease progression; ORR, objective response rate; (χ2), Chi-square test.